

Webinar #4:

MEDULLOBLASTOMA**16th Feb 2024 | 8:00PM – 9:30PM (GST +8 | Singapore Time)**

Program Name:	St. Jude-VIVA Survivorship Series 3 Webinar #4
Event Date:	Friday, 16th February 2024
Event Time:	8:00pm – 9:30pm (Singapore Time)

Programme Synopsis**Lecture Title:****Medulloblastoma***Dr Aditi Bagchi, St. Jude Children's Research Hospital*

With contemporary therapy approximately 75% of children with medulloblastoma will achieve long-term survival. This presentation will first trace the evolution of our understanding and treatment of childhood medulloblastoma from initial disease discovery to the implementation of innovative therapeutic approaches, which have increased survival. Despite improved survival rates, those who survive experience higher incidences of chronic health conditions that negatively affect quality and duration of survival. Common treatment-related morbidities observed in survivors, such as neurocognitive deficits, posterior fossa syndrome, infertility, a hearing loss will be described. Common challenges encountered in the clinical care of children with medulloblastoma will be featured in case presentations to facilitate discussion about provider and cultural perspectives about sharing information about potential late outcomes while offering hope to families for quality of survival. Finally, strategies to minimize the risks and toxicities of medulloblastoma therapy will be highlighted that leverage advances in radiation technology and genetics that are guiding the development of clinical trials employing a risk-stratification approach to optimize patient outcomes.



Presenter Bio

Dr Aditi Bagchi

**Departments of Oncology and Comprehensive Cancer Center
Neuro-Oncology Division
St. Jude Children's Research Hospital
USA**

Aditi Bagchi, MD, PhD, is a distinguished clinical researcher and pediatric neuro-oncologist. Her work seeks to advance collective understanding of pediatric brain tumors to develop treatment strategies that improve survival and reduce the burden of therapy related toxicity. Bagchi studied medicine at Kasturba Medical College in Mangalore, India. She then completed an Oncology fellowship at Helen DeVos Children's Hospital in Grand Rapids, MI and her Phd in Molecular Biology from Van Andel Research Institute, Grand Rapids, MI, before moving to St. Jude Children's Research Hospital. At St. Jude, Dr. Bagchi has steadily risen through the academic ranks. Now an assistant faculty member in the division of Neuro-Oncology, Dr. Bagchi studies the molecular and genomic characteristics of pediatric medulloblastomas, gliomas, and rare brain tumors affecting children with a primary focus on infants. She is the co-principal investigator of SJIMB21, a phase 2 study exploring the use of molecular and clinical risk-based therapy in infants and young children with medulloblastoma. Her research has been published in high impact journals like NEJM, Nature communication and Neuro-Oncology and provides insight into integration of molecular features to make accurate diagnosis and offer precise treatment.



Organising Chair/Moderator

Dr Melissa Hudson

**Member, St. Jude Faculty
Director, Cancer Survivorship Division
Co-Leader, Cancer Control & Survivorship Program
The Charles E. Williams Endowed Chair of Oncology-Cancer
Survivorship
St. Jude Children's Research Hospital
USA**